alexa Mutations In IDH1 And Its Prognostic Role For Patients With Glioblastoma | 16523
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

5th International Conference on Biomarkers & Clinical Research

Jiri Polivka Jr, Jiri Polivka, Martin Pesta and Ondrej Topolcan
Accepted Abstracts: J Mol Biomark Diagn
DOI: 10.4172/2155-9929.S1.023
Abstract
Introduction: Glioblastoma multiforme (GBM) is the most malignant primary brain tumor in adults with high mortality. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has only limited effectiveness with the median survival of patient with GBM 12.1-14.6 months. Recent GBM whole-genome studies revealed some novel prognostic and predictive biomarkers. The recurrent mutations in metabolic enzyme IDH - isocitrate dehydrogenase (isoforms IDH1 and IDH2) were identified in about 70%-80% of low-grade gliomas, in 50% of anaplastic gliomas and in approximately 5% of glioblastomas. The distinctive mutation IDH1 R132H was uncovered to be a strong prognostic biomarker for patients with malignant gliomas. Therefore we investigated the prognostic role of IDH1 R132 mutation in our GBM patients. Methods: The IDH1 R132H mutation status was studied in the tumor samples from 55 patients with GBM that were treated by the standard GBM protocol in the Faculty Hospital in Pilsen. The real-time PCR with TaqMan? Mutation Detection Assays and TaqMan? Mutation Detection IPC Reagent Kitwas used. The IDH1 R132 mutation status was compared with the progression free survival (PFS) and overall survival (OS) of patients. Results: The IDH1 R132H mutation was identified in 20 from 55 GBM tumor samples (36.4%). Patients with IDH R132H mutation had longer PFS-275 vs. 115 days (P<0.027, Log Rank), as well as longer OS - 390 vs. 235 days (P<0.05, Log Rank) than patients with wild-type IDH1. Summary: The IDH1 R132H mutation was observed in the interestingly higher number of patients with GBM that was previously published by other groups. The prognostic value of this mutation was also observed in our study. Patients with IDH1 R132 mutation had significantly longer PFS and OS than patients with wild-type IDH1. The IDH1 mutation status could be used as a strong prognostic factor for patients with GBM
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7